Tovanor Breezhaler

Country: European Union

Language: Slovenian

Source: EMA (European Medicines Agency)

Buy It Now

Active ingredient:

Glycopyrronium bromid

Available from:

Novartis Europharm Limited

ATC code:

R03BB06

INN (International Name):

glycopyrronium bromide

Therapeutic group:

Zdravila za obstruktivne pljučne bolezni,

Therapeutic area:

Pljučna bolezen, kronična obstruktivna bolezen

Therapeutic indications:

Zdravilo Tovanor Breezhaler je indicirano za zdravljenje bronhodilatatorjev za vzdrževanje simptomov pri odraslih bolnikih s kronično obstruktivno pljučno boleznijo (KOPB).

Product summary:

Revision: 15

Authorization status:

Pooblaščeni

Authorization date:

2012-09-28

Patient Information leaflet

                                22
9.
POSEBNA NAVODILA ZA SHRANJEVANJE
Shranjujte pri temperaturi do 25 °C.
Kapsule shranjujte v originalnem pretisnem omotu, da jih zaščitite
pred vlago. Iz pretisnega omota jih
vzemite šele tik pred uporabo.
10.
POSEBNI VARNOSTNI UKREPI ZA ODSTRANJEVANJE NEUPORABLJENIH
ZDRAVIL ALI IZ NJIH NASTALIH ODPADNIH SNOVI, KADAR SO POTREBNI
11.
IME IN NASLOV IMETNIKA DOVOLJENJA ZA PROMET Z ZDRAVILOM
Novartis Europharm Limited
Vista Building
Elm Park, Merrion Road
Dublin 4
Irska
12.
ŠTEVILKA(E) DOVOLJENJA (DOVOLJENJ) ZA PROMET
EU/1/12/790/001
6 kapsul + 1 inhalator
EU/1/12/790/007
10 kapsul + 1 inhalator
EU/1/12/790/002
12 kapsul + 1 inhalator
EU/1/12/790/003
30 kapsul + 1 inhalator
13.
ŠTEVILKA SERIJE
Lot
14.
NAČIN IZDAJANJA ZDRAVILA
Predpisovanje in izdaja zdravila je le na recept.
15.
NAVODILA ZA UPORABO
16.
PODATKI V BRAILLOVI PISAVI
Tovanor Breezhaler
23
17.
EDINSTVENA OZNAKA – DVODIMENZIONALNA ČRTNA KODA_ _
Vsebuje dvodimenzionalno črtno kodo z edinstveno oznako.
18.
EDINSTVENA OZNAKA – V BERLJIVI OBLIKI_ _
PC
SN
NN
_ _
24
PODATKI NA ZUNANJI OVOJNINI
ZUNANJA ŠKATLA SKUPNEGA PAKIRANJA (VKLJUČNO Z "BLUE BOX" PODATKI)
1.
IME ZDRAVILA
Tovanor Breezhaler 44 mikrogramov prašek za inhaliranje, trde kapsule
glikopironij (v obliki glikopironijevega bromida)
2.
NAVEDBA ENE ALI VEČ UČINKOVIN
Ena kapsula vsebuje 50 mikrogramov glikopironija. Količina vnešenega
glikopironija znaša
44 mikrogramov.
3.
SEZNAM POMOŽNIH SNOVI
Vsebuje tudi: laktozo in magnezijev stearat.
Za več podatkov glejte Navodilo za uporabo.
4.
FARMACEVTSKA OBLIKA IN VSEBINA
prašek za inhaliranje, trda kapsula
Skupno pakiranje: 90 kapsul (3 pakiranja po 30 x 1) in 3 inhalatorji.
Skupno pakiranje: 96 kapsul (4 pakiranja po 24 x 1) in 4 inhalatorji.
Skupno pakiranje: 150 kapsul (15 pakiranj po 10 x 1) in 15
inhalatorjev.
Skupno pakiranje: 150 kapsul (25 pakiranj po 6 x 1) in 25
inhalatorjev.
5.
POSTOPEK IN POT(I) UPORABE ZDRAVILA
Uporabljajte samo s priloženim inhalatorjem.
Kapsul ne smete pogoltniti.
Pred uporabo preberite priloženo navo
                                
                                Read the complete document
                                
                            

Summary of Product characteristics

                                1
PRILOGA I
POVZETEK GLAVNIH ZNAČILNOSTI ZDRAVILA
2
1.
IME ZDRAVILA
Tovanor Breezhaler 44 mikrogramov prašek za inhaliranje, trde kapsule
2.
KAKOVOSTNA IN KOLIČINSKA SESTAVA
Ena kapsula vsebuje 63 mikrogramov glikopironijevega bromida, kar
ustreza 50 mikrogramom
glikopironija.
En odmerek glikopironijevega bromida, ki pride skozi ustnik
inhalatorja, vsebuje 55 mikrogramov
glikopironijevega bromida, kar ustreza 44 mikrogramom glikopironija.
Pomožna(e) snov(i) z znanim učinkom:
Ena kapsula vsebuje 23,6 mg laktoze (v obliki monohidrata).
Za celoten seznam pomožnih snovi glejte poglavje 6.1.
3.
FARMACEVTSKA OBLIKA
prašek za inhaliranje, trda kapsula (prašek za inhaliranje)
Prozorne oranžne kapsule, ki vsebujejo bel prašek in imajo
natisnjeno črno oznako zdravila "GPL50"
nad črno črto in črn zaščitni znak družbe (
) pod črno črto.
4.
KLINIČNI PODATKI
4.1
TERAPEVTSKE INDIKACIJE
Zdravilo Tovanor Breezhaler je indicirano kot vzdrževalno
brohodilatatorno zdravljenje za lajšanje
simptomov pri odraslih bolnikih s kronično obstruktivno pljučno
boleznijo (KOPB).
4.2
ODMERJANJE IN NAČIN UPORABE
Odmerjanje
Priporočeni odmerek je inhalacija vsebine ene kapsule enkrat na dan z
uporabo inhalatorja Tovanor
Breezhaler.
Zdravilo Tovanor Breezhaler je priporočeno jemati vsak dan ob istem
času. V primeru izpuščenega
odmerka je treba naslednji odmerek vzeti čimprej. Bolnikom je treba
naročiti, naj ne vzamejo več kot
enega odmerka v istem dnevu.
Posebne skupine bolnikov
_Starejši ljudje _
Starejši bolniki (stari 75 let ali več) lahko uporabljajo zdravilo
Tovanor Breezhaler v priporočenem
odmerku (glejte poglavje 4.8).
_Okvara ledvic _
Bolniki z blago do zmerno okvaro ledvic lahko uporabljajo zdravilo
Tovanor Breezhaler v
priporočenem odmerku. Bolniki s hudo okvaro ledvic in bolniki, ki
imajo končno ledvično odpoved in
potrebujejo dializno zdravljenje, smejo uporabljati zdravilo Tovanor
Breezhaler samo v primeru, da
pričakovana korist presega potencialno tveganje, ker je v tej skupini
bolnikov siste
                                
                                Read the complete document
                                
                            

Documents in other languages

Patient Information leaflet Patient Information leaflet Bulgarian 09-11-2021
Summary of Product characteristics Summary of Product characteristics Bulgarian 09-11-2021
Public Assessment Report Public Assessment Report Bulgarian 09-07-2018
Patient Information leaflet Patient Information leaflet Spanish 09-11-2021
Public Assessment Report Public Assessment Report Spanish 09-07-2018
Patient Information leaflet Patient Information leaflet Czech 09-11-2021
Public Assessment Report Public Assessment Report Czech 09-07-2018
Patient Information leaflet Patient Information leaflet Danish 09-11-2021
Public Assessment Report Public Assessment Report Danish 09-07-2018
Patient Information leaflet Patient Information leaflet German 09-11-2021
Public Assessment Report Public Assessment Report German 09-07-2018
Patient Information leaflet Patient Information leaflet Estonian 09-11-2021
Public Assessment Report Public Assessment Report Estonian 09-07-2018
Patient Information leaflet Patient Information leaflet Greek 09-11-2021
Public Assessment Report Public Assessment Report Greek 09-07-2018
Patient Information leaflet Patient Information leaflet English 09-11-2021
Public Assessment Report Public Assessment Report English 09-07-2018
Patient Information leaflet Patient Information leaflet French 09-11-2021
Public Assessment Report Public Assessment Report French 09-07-2018
Patient Information leaflet Patient Information leaflet Italian 09-11-2021
Public Assessment Report Public Assessment Report Italian 09-07-2018
Patient Information leaflet Patient Information leaflet Latvian 09-11-2021
Public Assessment Report Public Assessment Report Latvian 09-07-2018
Patient Information leaflet Patient Information leaflet Lithuanian 09-11-2021
Summary of Product characteristics Summary of Product characteristics Lithuanian 09-11-2021
Public Assessment Report Public Assessment Report Lithuanian 09-07-2018
Patient Information leaflet Patient Information leaflet Hungarian 09-11-2021
Summary of Product characteristics Summary of Product characteristics Hungarian 09-11-2021
Public Assessment Report Public Assessment Report Hungarian 09-07-2018
Patient Information leaflet Patient Information leaflet Maltese 09-11-2021
Public Assessment Report Public Assessment Report Maltese 09-07-2018
Patient Information leaflet Patient Information leaflet Dutch 09-11-2021
Public Assessment Report Public Assessment Report Dutch 09-07-2018
Patient Information leaflet Patient Information leaflet Polish 09-11-2021
Public Assessment Report Public Assessment Report Polish 09-07-2018
Patient Information leaflet Patient Information leaflet Portuguese 09-11-2021
Summary of Product characteristics Summary of Product characteristics Portuguese 09-11-2021
Public Assessment Report Public Assessment Report Portuguese 09-07-2018
Patient Information leaflet Patient Information leaflet Romanian 09-11-2021
Public Assessment Report Public Assessment Report Romanian 09-07-2018
Patient Information leaflet Patient Information leaflet Slovak 09-11-2021
Public Assessment Report Public Assessment Report Slovak 09-07-2018
Patient Information leaflet Patient Information leaflet Finnish 09-11-2021
Public Assessment Report Public Assessment Report Finnish 09-07-2018
Patient Information leaflet Patient Information leaflet Swedish 09-11-2021
Public Assessment Report Public Assessment Report Swedish 09-07-2018
Patient Information leaflet Patient Information leaflet Norwegian 09-11-2021
Summary of Product characteristics Summary of Product characteristics Norwegian 09-11-2021
Patient Information leaflet Patient Information leaflet Icelandic 09-11-2021
Summary of Product characteristics Summary of Product characteristics Icelandic 09-11-2021
Patient Information leaflet Patient Information leaflet Croatian 09-11-2021
Public Assessment Report Public Assessment Report Croatian 09-07-2018

Search alerts related to this product